Importantly, the tumor-promoting effects of CXCL3 were significantly suppressed by treatment with the mechanistic target of rapamycin (mTOR) inhibitor Torin 1, supporting the notion that targeting this pathway may provide therapeutic benefit in liver cancer. This evidence concerns the gene CXCL3 and liver cancer.